AptarGroup, Inc. logo

AptarGroup, Inc.

ATR

NYSEHealthcareMedical - Instruments & Supplies

Previous close

$134.8

+$1.84 · +1.38%

Aug 21, 4:00 PM ET

ATR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

85

Deep Value

Momentum

42

Neutral

Sentiment

60

Mixed

Risk resilience

75

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (including prescription drugs, consumer health care, and injectables), alongside the food and beverage markets. Its operations are structured into three key segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma division offers critical components for the pharmaceutical industry, including pumps for nasal allergy remedies, metered dose inhaler valves vital for managing respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), elastomeric primary packaging for injectables, and sophisticated active material science innovations. The Beauty + Home segment primarily supplies the personal care and home care sectors with essential products such as pumps, various closures, aerosol valves, accompanying accessories, and sealing mechanisms. It also furnishes the beauty market with pumps and decorative elements. For the food and beverage industries, its Food + Beverage segment delivers a variety of dispensing and non-dispensing closures, specialized elastomeric flow control components, spray pumps, and aerosol valves. AptarGroup markets its offerings globally, utilizing its internal sales team, complemented by independent representatives and distributors across Asia, Europe, Latin America, and North America. The company is engaged in a strategic partnership with PureCycle Technologies LLC to pioneer the integration of ultra-pure recycled polypropylene into advanced dispensing applications. Additionally, it collaborates with Sonmol on the development of a digital platform providing therapies and services, with a particular focus on respiratory and other health conditions. Established in 1992, AptarGroup, Inc. maintains its corporate headquarters in Crystal Lake, Illinois.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Stephan Tanda
Listed since
Apr 23, 1993
Employees
14,000

Market position

Day range

Current $134.8

52-week range

Current $134.8

Open
$134.12
Previous close
$132.96
Volume
225.82K
0.45× average
Average volume
498.37K
Average daily volume
Market cap
8.6B USD
Beta
0.38
Market reference 1
50-day average
$128.94
+4.55% above average
200-day average
$125.79
+7.16% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
9.15B USD
EV / EBITDA
11×
Earnings yield
4.90%
Free cash flow yield
3.74%

Profitability & efficiency

Return on equity
14.72%
Return on assets
7.48%
Return on invested capital
9.24%

Financial health

Current ratio
1.62×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends41%29%16%4%Gross margin, FY2021: 35.84%Gross margin, FY2022: 35.03%Gross margin, FY2023: 36.23%Gross margin, FY2024: 37.83%Gross margin, FY2025: 29.58%Operating margin, FY2021: 10.76%Operating margin, FY2022: 11.42%Operating margin, FY2023: 11.58%Operating margin, FY2024: 13.86%Operating margin, FY2025: 13.56%Net margin, FY2021: 7.56%Net margin, FY2022: 7.20%Net margin, FY2023: 8.16%Net margin, FY2024: 10.45%Net margin, FY2025: 10.40%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 35.84%. Gross margin FY2022 35.03%. Gross margin FY2023 36.23%. Gross margin FY2024 37.83%. Gross margin FY2025 29.58%. Operating margin FY2021 10.76%. Operating margin FY2022 11.42%. Operating margin FY2023 11.58%. Operating margin FY2024 13.86%. Operating margin FY2025 13.56%. Net margin FY2021 7.56%. Net margin FY2022 7.20%. Net margin FY2023 8.16%. Net margin FY2024 10.45%. Net margin FY2025 10.40%.

Income trends

Revenue

3.78B USD+5.42%

Operating income

512.34M USD+3.19%

Net income

392.79M USD+4.87%
Income trends across reported periods4.13B USD2.72B USD1.3B USD−114.5M USDRevenue, FY2021: 3.23B USDRevenue, FY2022: 3.32B USDRevenue, FY2023: 3.49B USDRevenue, FY2024: 3.58B USDRevenue, FY2025: 3.78B USDOperating income, FY2021: 347.35M USDOperating income, FY2022: 379.27M USDOperating income, FY2023: 404.02M USDOperating income, FY2024: 496.5M USDOperating income, FY2025: 512.34M USDNet income, FY2021: 244.1M USDNet income, FY2022: 239.29M USDNet income, FY2023: 284.49M USDNet income, FY2024: 374.54M USDNet income, FY2025: 392.79M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 3.23B USD. Revenue FY2022 3.32B USD. Revenue FY2023 3.49B USD. Revenue FY2024 3.58B USD. Revenue FY2025 3.78B USD. Operating income FY2021 347.35M USD. Operating income FY2022 379.27M USD. Operating income FY2023 404.02M USD. Operating income FY2024 496.5M USD. Operating income FY2025 512.34M USD. Net income FY2021 244.1M USD. Net income FY2022 239.29M USD. Net income FY2023 284.49M USD. Net income FY2024 374.54M USD. Net income FY2025 392.79M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue3.78B USD3.58B USD3.49B USD3.32B USD3.23B USD
Cost of goods sold2.66B USD2.23B USD2.22B USD2.16B USD2.07B USD
Gross profit1.12B USD1.36B USD1.26B USD1.16B USD1.16B USD
Research and development105.1M USD99.8M USD
Selling, general, and administrative499.94M USD582.23M USD565.78M USD544.26M USD551.24M USD
Operating expenses605.04M USD859.01M USD859.38M USD784.57M USD809.34M USD
Interest income11.68M USD12.1M USD4.37M USD2.7M USD3.67M USD
Interest expense52.74M USD43.9M USD40.42M USD40.83M USD30.28M USD
Depreciation and amortization287.36M USD263.78M USD248.59M USD233.71M USD234.85M USD
Operating income512.34M USD496.5M USD404.02M USD379.27M USD347.35M USD
Net income392.79M USD374.54M USD284.49M USD239.29M USD244.1M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+5.74%
11 comparable reports
Latest EPS result
1.42
Estimate 1.35 · Beat by 5.19%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.731.511.31.08Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 6, 2025: actual 1.52, estimate 1.28, surprise +18.75%, Beat. Q2 2025, reported May 1, 2025: actual 1.2, estimate 1.16, surprise +3.45%, Beat. Q3 2025, reported Jul 31, 2025: actual 1.66, estimate 1.58, surprise +5.06%, Beat. Q4 2025, reported Oct 30, 2025: actual 1.62, estimate 1.57, surprise +3.18%, Beat. Q1 2026, reported Feb 5, 2026: actual 1.25, estimate 1.24, surprise +0.81%, Beat. Q2 2026, reported Apr 30, 2026: actual 1.19, estimate 1.15, surprise +3.48%, Beat. Q3 2026, reported Jul 30, 2026: actual 1.42, estimate 1.35, surprise +5.19%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 1.46, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.07B980.72M893.87M807.03MQ1 '25MissQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 6, 2025: actual 848.09M USD, estimate 852.26M USD, surprise -0.49%, Miss. Q2 2025, reported May 1, 2025: actual 887.31M USD, estimate 898.64M USD, surprise -1.26%, Miss. Q3 2025, reported Jul 31, 2025: actual 966.01M USD, estimate 959M USD, surprise +0.73%, Beat. Q4 2025, reported Oct 30, 2025: actual 961.13M USD, estimate 880.25M USD, surprise +9.19%, Beat. Q1 2026, reported Feb 5, 2026: actual 962.74M USD, estimate 878.58M USD, surprise +9.58%, Beat. Q2 2026, reported Apr 30, 2026: actual 982.87M USD, estimate 955.95M USD, surprise +2.82%, Beat. Q3 2026, reported Jul 30, 2026: actual 1.03B USD, estimate 1.01B USD, surprise +1.69%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 982.81M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$160

18.69% upside
Past 12 months12-month forecast

Price history unavailable

High $160Average $160Low $160

ATR news

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$1.83

2025 complete year+22.0% since 2021

2026 partial: $1.44

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jul 30, 2026

$0.48

Quarterly

Record Jul 30, 2026 · Payment Aug 20, 2026

Dividend

Ex-dividend May 6, 2026

$0.48

Quarterly

Record May 6, 2026 · Payment May 27, 2026

Dividend

Ex-dividend Feb 4, 2026

$0.48

Quarterly

Record Feb 4, 2026 · Payment Feb 25, 2026

Dividend

Ex-dividend Oct 23, 2025

$0.48

Quarterly

Record Oct 23, 2025 · Payment Nov 13, 2025

Dividend

Ex-dividend Jul 24, 2025

$0.45

Quarterly

Record Jul 24, 2025 · Payment Aug 14, 2025

Dividend

Ex-dividend May 1, 2025

$0.45

Quarterly

Record May 1, 2025 · Payment May 22, 2025

ATR peers

ETFs holding ATR

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research ATR

research.disclaimer